Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression

Journal of Gastroenterology

Volumn 48, Issue 11, 2013, Pages 1283-1292

  Koda, Masahiko ^a   Tokunaga, Shiho ^a   Miyoshi, Kennichi ^a   Kishina, Manabu ^a   Fujise, Yuki ^a   Kato, Jun ^a   Matono, Tomomitsu ^a   Murawaki, Yoshikazu ^a   Kakite, Suguru ^b   Yamashita, Eijiro ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Ablative margin; Ferucarbotran; Local tumor progression; Magnetic resonance imaging; Radiofrequency ablation

Indexed keywords

EPIRUBICIN; FERUCARBOTRAN;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTRODE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; DEXTRANS; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; POSTOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84889885752     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0747-0     Document Type: Article

References (27)

1. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195:829-36.
2. Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol. 2007;37:658-72.
3. Peng Z-W, Zhang Y-J, Chen M-S, Liang H-H, Li J-Q, Zhang Y-Q, et al. Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg Oncol. 2008;17:23-31.
4. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006;9:125-32.
5. Park M-H, Rhim H, Kim Y-S, Choi D, Lim HK, Lee WF. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. RadioGraphics. 2008;28:379-92.
6. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathological features. Cancer. 2002;95:1931-7.
7. Ikeda K, Seki T, Umehara H, Inokuchi R, Tamai T, Sakaida N, et al. Clinicopathological study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol. 2007;31:485-91.
8. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation. Multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242:158-71.
9. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the AM and prediction of local tumor progression and its validation. J Gastroenterol. 2011;46:1418-26.
10. Mori K, Fukuda K, Asaoka H, Ueda T, Kunimatsu A, Okamoto Y, et al. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran-feasibility study. Radiology. 2009;251:557-65.
11. Liu K, He X, Lei X-Z, Zhao L-S, Tang H, Liu L, et al. Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol. 2003;9:1946-9.
12. Kakite S, Fujii S, Nakamatsu S, Kanasaki Y, Yamashita E, Matsusue E, et al. Usefulness of administration of SPIO prior to RF ablation for evaluation of the therapeutic effect: an experimental study using miniature pigs. Eur J Radiol. 2011;78:282-6.
13. Koda M, Tokunaga S, Fujise Y, Kato J, Matono T, Sugihara T, et al. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol. 2012;81:1400-4.
14. Tokunaga S, Koda M, Matono T, Sugihara T, Nagahara T, Ueki M, et al. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT. Br J Radiol. 2012;85:745-52.
15. Koda M, Ueki M, Maeda Y, Mimura K, Okamoto K, Matsunaga Y, et al. Percutaneous sonographically guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma located under the diaphragm. AJR. 2004;183:583-8.
16. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR. 2007;188:480-8.
17. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005;235:728-39.
18. Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97:1253-62.
19. Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol. 2003;38:977-81.
20. Zytoon AA, Ishii H, Murakami K, El-Kholy MR, Furuse J, El-Dorry A, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol. 2007;37:658-72.
21. Kei SK, Rhim H, Choi D, Lee WJ, Lim HK, Kim Y. Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence. AJR. 2008;190:1544-51.
22. Sartori S, Tombesi P, Macario F, Nielsen I, Tassinari D, Catellani M, et al. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. Radiology. 2008;248:670-9.
23. Park Y, Kim Y, Rhim H, Lim HK, Choi D, Lee WJ. Arterial enhancement of hepatocellular carcinoma before radiofrequency ablation as a predictor of postablation local tumor progression. AJR. 2009;193:757-63.
24. Kim Y, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR. 2010;195:758-65.
25. Song I, Rhim H, Lim HK, Kim Y, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol. 2009;19:2630-40.
26. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res. 2003;26:142-7.
27. Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res. 2012;42:1058-64.